Viewing nowEvicasa 20 mg (Memantine Hydrochloride)
Memantine Hydrochloride 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

MFDS item code 202107380 · Approved 2021.11.10 · Insurance code 668000160
Treatment of moderate to severe Alzheimer’s disease
This medication is used for patients with moderate to severe Alzheimer's disease. Alzheimer's disease is characterized by memory loss and cognitive impairment, and this medication helps to alleviate symptoms and improve the patient's ability to carry out daily activities. It supports the patient in maintaining a more stable condition by slowing the progression of symptoms.
This medicine is administered orally once daily, at the same time each day. If needed, this medicine may be administered twice daily. This medicine may be taken regardless of food intake. Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (day 1~7): Administer 5mg daily for 7 days. Week 2 (day 8~14): Administer 10mg daily for 7 days. Week 3 (day 15~21): Administer 15mg daily for 7 days. From week 4 onward: Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. Based on clinical data, the recommended dose for elderly patients aged 65 years or older is 20mg daily. No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced to 10mg. If well tolerated, the dose may be increased to 20mg daily in accordance with the standard dose-escalation schedule, after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance: 5-29 mL/min), the daily dose should be reduced to 10mg. No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since there are no data on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.
This medication should not be used in patients with known allergic reactions to any of its components. It should also not be administered to patients with severe liver impairment or severe renal impairment. Special caution is needed in patients with epilepsy or those with a history of seizures. Co-administration with other medications that have similar effects may increase the severity of side effects, so such combinations should be avoided. Significant changes in urine acidity may affect the excretion of this medication, requiring medical supervision. Patients with uncontrolled heart disease or hypertension should consult with a healthcare provider before using this medication. While taking this medication, side effects such as dizziness, headache, constipation, drowsiness, and elevated blood pressure may occur, so physical condition should be closely monitored. Neurological side effects such as mental confusion or hallucinations can occur rarely, and any unusual symptoms should be reported to a healthcare provider immediately. There is potential for interactions with other medications, so it is essential to inform your healthcare provider of any other medications you are currently taking. Women who are pregnant or may become pregnant should consult with a healthcare provider before taking this medication, and breastfeeding women are advised to discontinue breastfeeding. The safety and efficacy of this medication have not been established in children and adolescents under 18 years, so it is advisable to avoid use. In case of overdose, severe symptoms such as coma, seizures, and hallucinations may occur, so it is crucial to adhere to the prescribed dosage and visit a hospital immediately in case of overdose. This medication may affect the patient's reaction time, so caution is needed when driving or operating machinery. Store this medication out of the reach of children and do not transfer it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from exposure to air and moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage will ensure the safety of the medication's efficacy.
Pink oval film-coated tablet imprinted with "20" on one side and "MEM" on the other side.
28 tablets/box [14 tablets/PTP x 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowMemantine Hydrochloride 10mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Memantine Hydrochloride 1g
Solution · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Lundbeck Korea Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Donghwa Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Youngjin Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Unimed Pharmaceutical Co., Ltd.

Memantine Hydrochloride 10mg
Tablet · Prescription medication
Myongin Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.